Financials Immatics N.V.

Equities

IMTX

NL0015285941

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
10.01 USD +2.35% Intraday chart for Immatics N.V. -1.96% -4.94%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 186.9 678.8 845.5 663.9 891.4 1,031 - -
Enterprise Value (EV) 1 186.9 435.4 710 289.7 891.4 608.6 617.3 617.4
P/E ratio -0.35 x -1.92 x -8.25 x 14.7 x -8.08 x -6.83 x -6.99 x -6.7 x
Yield - - - - - - - -
Capitalization / Revenue 9.35 x 18.5 x 22.1 x 3.57 x 15.2 x 16.1 x 16.5 x 19.1 x
EV / Revenue 9.35 x 11.8 x 18.5 x 1.56 x 15.2 x 9.48 x 9.85 x 11.4 x
EV / EBITDA - -5.67 x -7.96 x 7.29 x -8.69 x -5.15 x -3.87 x -2.49 x
EV / FCF - -3.99 x -7.43 x - - -4.79 x -4.44 x -3.97 x
FCF Yield - -25.1% -13.5% - - -20.9% -22.5% -25.2%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 17,969 62,909 62,909 76,227 84,656 102,985 - -
Reference price 2 10.40 10.79 13.44 8.710 10.53 10.01 10.01 10.01
Announcement Date 4/16/20 3/30/21 3/23/22 3/21/23 3/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 19.98 36.77 38.29 186 58.62 64.21 62.66 54.03
EBITDA 1 - -76.81 -89.24 39.74 -102.6 -118.1 -159.5 -247.5
EBIT 1 - -82.02 -95.04 32.24 -110.4 -137.5 -169.3 -221.1
Operating Margin - -223.07% -248.24% 17.33% -188.39% -214.17% -270.17% -409.28%
Earnings before Tax (EBT) 1 - -270.1 -102.8 - -105.3 -150 -169.5 -185.6
Net income 1 - -269.5 -102.8 40.38 -105.3 -139.6 -146.6 -185.6
Net margin - -732.92% -268.49% 21.71% -179.63% -217.43% -233.9% -343.6%
EPS 2 -29.38 -5.612 -1.630 0.5920 -1.303 -1.465 -1.433 -1.494
Free Cash Flow 1 - -109.1 -95.6 - - -127.1 -139.1 -155.4
FCF margin - -296.72% -249.7% - - -197.9% -221.97% -287.64%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 4/16/20 3/30/21 3/23/22 3/21/23 3/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 7.307 17.32 110.4 17.59 15.55 40.53 10.64 24.39 6.339 17.28 22.09 14.35 14.03 13.47
EBITDA - - - - - - - - - -28.14 - - - -
EBIT 1 -26.08 -17.69 73.47 -17.02 -22.64 0.0484 -28.71 -15.62 -35.58 -30.09 -27.48 -34.81 -37.1 -39.66
Operating Margin -356.99% -102.12% 66.56% -96.76% -145.58% 0.12% -269.8% -64.04% -561.37% -174.07% -124.41% -242.63% -264.43% -294.4%
Earnings before Tax (EBT) 1 -30.85 -18.49 91.89 -13.12 -21.04 - -21.45 -26.85 -28.33 -28.39 -34.67 -36.29 -33.82 -45.34
Net income 1 -30.85 -18.49 91.89 -14.29 -21.61 -14.24 -21.45 -26.85 -28.33 -28.39 -29.41 -36.36 -35.14 -43.29
Net margin -422.21% -106.74% 83.24% -81.21% -139.01% -35.15% -201.58% -110.09% -447% -164.24% -133.13% -253.4% -250.47% -321.31%
EPS 2 -0.4876 -0.2863 1.448 -0.2248 -0.3304 -0.2476 -0.2824 -0.3491 -0.3423 -0.3257 -0.2877 -0.3527 -0.3380 -0.4140
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/16/21 3/23/22 6/2/22 8/9/22 11/17/22 3/21/23 5/16/23 8/17/23 11/14/23 3/21/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 243 135 374 - 422 414 413
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -109 -95.6 - - -127 -139 -155
ROE (net income / shareholders' equity) - - -167% 31.6% - -80.8% - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share 2 - -2.090 -1.430 1.580 - -0.9800 -1.160 -
Capex 1 - 8.7 5.62 - - 27.1 10.8 8.13
Capex / Sales - 23.67% 14.67% - - 42.13% 17.28% 15.04%
Announcement Date 4/16/20 3/30/21 3/23/22 3/21/23 3/21/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.01 USD
Average target price
19 USD
Spread / Average Target
+89.81%
Consensus
  1. Stock Market
  2. Equities
  3. IMTX Stock
  4. Financials Immatics N.V.